In Population 1 , genital mycotic infection incidence was higher with canagliflozin 100 and 300mg than placebo ( 95 % confidence intervals excluded zero ) in females ( 10.4 % , 11.4 % , 3.2 % ) and males ( 4.2 % , 3.7 % , 0.6 % ) .